| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 74.72 mm | 74.72 mm | 74.72 mm | 74.72 mm | 74.72 mm | 74.72 mm |
| Cash burn (monthly) | 3.18 mm | 4.32 mm | 5.04 mm | 4.40 mm | 3.43 mm | 3.25 mm |
| Cash used (since last report) | 6.58 mm | 8.95 mm | 10.44 mm | 9.12 mm | 7.10 mm | 6.74 mm |
| Cash remaining | 68.13 mm | 65.76 mm | 64.27 mm | 65.59 mm | 67.61 mm | 67.98 mm |
| Runway (months of cash) | 21.4 | 15.2 | 12.8 | 14.9 | 19.7 | 20.9 |
| 13F holders | Current |
|---|---|
| Total holders | 40 |
| Opened positions | 7 |
| Closed positions | 14 |
| Increased positions | 6 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 26.16 bn |
| Total shares | 55.33 mm |
| Total puts | 190.00 k |
| Total calls | 0.00 |
| Total put/call ratio | Infinity |
| Largest owners | Shares | Value |
|---|---|---|
| Venrock Healthcare Capital Partners II | 20.70 mm | $26.49 mm |
| Growth Equity Opportunities 17 | 16.30 mm | $35.05 mm |
| Lincoln Park Capital Fund | 4.61 mm | $3.68 mm |
| Biotechnology Value Fund L P | 2.78 mm | $9.53 mm |
| TCG Crossover Management | 2.68 mm | $8.06 bn |
| TCG Crossover GP II | 2.03 mm | $6.97 mm |
| StemPoint Capital | 1.85 mm | $4.90 bn |
| Vanguard | 1.79 mm | $5.40 bn |
| Great Point Partners | 674.08 k | $2.03 bn |
| BlackRock | 412.13 k | $1.24 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Dec 24 | Cynthia Lynn Anderson | Common Stock | Grant | Acquire A | No | No | 2.5075 | 2,592 | 6.50 k | 6,184 |
| 31 Dec 24 | Joshua S. Prince | Common Stock | Grant | Acquire A | No | No | 2.5075 | 3,310 | 8.30 k | 5,981 |
| 6 Sep 24 | Saxe Jon S | Stock Option Common Stock | Grant | Acquire A | No | No | 3.25 | 14,100 | 45.83 k | 14,100 |
| 6 Sep 24 | Cunningham Ann Michelle | Stock Option Common Stock | Grant | Acquire A | No | No | 3.25 | 14,100 | 45.83 k | 14,100 |
| 6 Sep 24 | Gin Jerry B | Stock Option Common Stock | Grant | Acquire A | No | No | 3.25 | 14,100 | 45.83 k | 14,100 |
